(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 69.8MM | +23% |
Operating Income | -54MM | -61% |
Operating Expenses | 123.8MM | - |
Net Income | -55.7MM | -61% |
R&D | 20.4MM | +56% |
G&A | 85.2MM | +23% |
Amortization | 1.6MM | -10% |
Interest Expense | 5.4MM | +6% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
NASHVILLE, Tenn., April 12, 2024--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
Key Insights Institutions' substantial holdings in Revance Therapeutics implies that they have significant influence...
NASHVILLE, Tenn., March 27, 2024--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NASHVILLE, Tenn., March 04, 2024--Revance Announces Pricing of $100 Million Public Offering of Common Stock
NASHVILLE, Tenn., March 04, 2024--Revance Announces Proposed Public Offering of Common Stock
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference […]
Revance Therapeutics, Inc. ( NASDAQ:RVNC ) investors will be delighted, with the company turning in some strong numbers...
Revance Therapeutics ( NASDAQ:RVNC ) Full Year 2023 Results Key Financial Results Revenue: US$234.0m (up 77% from FY...
Q4 2023 Revance Therapeutics Inc Earnings Call
Robust Sales Drive 40% Quarterly and 77% Annual Revenue Increases